Kezar Life Sciences, Inc. Common Stock
KZRKezar Life Sciences, Inc. (KZR) is a biotechnology company focused on discovering and developing novel immunomodulatory therapies for the treatment of autoimmune diseases, cancer, and inflammatory conditions. The company leverages its expertise in immune modulation and precision medicine to develop targeted treatments aimed at driving significant therapeutic benefits for patients.
Company News
Kezar Life Sciences announced a strategic review after the FDA blocked plans for a clinical trial of zetomipzomib for autoimmune hepatitis, requiring additional pharmacokinetic studies that would delay trials by approximately 2 years.
Upgrades According to OTR Global, the prior rating for Generac Holdings Inc (NYSE:GNRC) was changed from Negative to Mixed. In the second quarter, Generac Hldgs showed an EPS of $1.08, compared to $2.99 from the year-ago quarter. At the moment, the stock has a 52-week-high of $186.65 and a 52-week-low of $86.29. Generac Hldgs closed at $101.71 at...
Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.
Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer. Neptune Wellness Solutions Inc. (NASDAQ: NEPT) shares rose 28.5% to $5.03 in pre-market trading ...
